RECURRENT ENDOMETRIAL SEROUS ADENOCARCINOMA
Clinical trials for RECURRENT ENDOMETRIAL SEROUS ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT ENDOMETRIAL SEROUS ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT ENDOMETRIAL SEROUS ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered virus targets Hard-to-Treat endometrial cancer in early trial
Disease control OngoingThis early-phase trial tests a specially designed virus (VSV-hIFNbeta-NIS) that is meant to infect and kill cancer cells while leaving healthy cells alone. It is given intravenously to people with stage IV or recurrent endometrial cancer. The main goals are to find the safest dos…
Matched conditions: RECURRENT ENDOMETRIAL SEROUS ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
New drug combo shows promise for recurrent uterine cancer
Disease control OngoingThis early-phase trial tests whether combining two drugs—niraparib and dostarlimab—can shrink or control a rare, aggressive uterine cancer that has returned or not gone away. The study enrolled 8 adults who had already tried standard chemotherapy. The goal is to see how many pati…
Matched conditions: RECURRENT ENDOMETRIAL SEROUS ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Casey Cosgrove • Aim: Disease control
Last updated May 07, 2026 18:41 UTC
-
Immunotherapy plus chemo shows promise for tough endometrial cancers
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (paclitaxel and carboplatin) helps people with advanced or recurrent endometrial cancer live longer without the cancer growing. About 813 participants with stage III, IV, or recurrent di…
Matched conditions: RECURRENT ENDOMETRIAL SEROUS ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 05, 2026 11:54 UTC